⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of FyoniBio GmbH and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
FyoniBio GmbH
↗Berlin, Germany
FyoniBio GmbH is a German contract development and clinical laboratory organization based in Berlin. Originally the service unit of the biotechnology company Glycotope, it became an independent entity in early 2022. The company specializes in biologics development, offering services ranging from cell line development and process development to comprehensive analytical characterization and clinical bioanalysis.
FyoniBio leverages proprietary technology platforms, including the CHOnamite® CHO platform for high-yield production, the CHOFlow® platform for ADCC-enhanced antibodies, and the human GlycoExpress® (GEX®) platform for complex glycoproteins. The company operates under ISO 9001:2015 certification and provides GCLP-compliant clinical sample analysis, supporting pharmaceutical and biotech partners from early-stage research through clinical trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2022
Ownership:private
Status:operating
PIPELINE
Stage:N/A
Lead Drug Stage:N/A
Modalities:Monoclonal antibodies, Fusion proteins, Oligonucleotides, Peptides, Complex glycoproteins
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:INITS (Strategic collaboration for end-to-end R&D to GMP services), Propanc Biopharma (Service agreement for PK assay validation), BioLamina (Collaboration on cell therapy), Alder Therapeutics (Collaboration on manufacturing process)
COMPETITION
Position:Niche Player
Competitors:Lonza, Catalent, Sartorius, Charles River Laboratories
LEADERSHIP
Key Executives:
Lars Stöckl - Managing Director
Hans Baumeister - Managing Director
LINKS
Website:fyonibio.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with FyoniBio GmbH. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.